PT-141 (Topical formulation)
ExperimentalCompounded topical melanocortin / researchExperimental
Compounded topical PT-141 products. Systemic absorption and efficacy are not established like the approved SC autoinjector.
For research use only.
Key Facts
- CAS
- 189691-06-3
- Molecular Weight (MW)
- 1025.2 g/mol
- Half-life
- Topical kinetics not published; peptide absorption limited
- Unit
- mcg
- Administration Route
- Topical / transdermal (research)
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- MC4R
Overview
Compounded topical PT-141 products. Systemic absorption and efficacy are not established like the approved SC autoinjector.
Protocol
- Dosage Range
- Not established for topical route
- Frequency
- —
- Cycle
- —
- Administration Route
- Topical / transdermal (research)
- Reconstitution Guide
- —
Science
Mechanism of Action
Same MC4R agonist peptide; topical delivery has uncertain bioavailability versus 1.75 mg SC Vyleesi.
Targets
MC4R
Studies
- Bremelanotide SC HSDD trials— Journal/year not available
Benefits
Non-injectable research/compounding interest
Potential Side Effects
- Local irritation
- Unpredictable systemic effects
References
- Vyleesi label (approved route is SC)External link · Year —